Karyopharm Therapeutics (KPTI) AI Stock Analysis

• Market Cap: $34.86M
• Dividend Yield: N/A
• Average Volume (3M): 192.02K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.41
• Revenue Growth: -5.77%
• EPS Growth: -22.78%
• Country: US
• Employees: 279
• Sector: Healthcare
• Sector Strength: 41
• Industry: Biotechnology
• EPS (TTM): -4.32
• Shares Outstanding: 8,671,278
• 10 Day Avg. Volume: 125,307
• 30 Day Avg. Volume: 192,021
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 5.05
• Enterprise Value/Revenue: 1.28
• Enterprise Value/Gross Profit: 1.33
• Enterprise Value/Ebitda: -2.29
• 1Y Price Target: $17.25
• Price Target Upside: 287.64% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 5

• Rating: 41 Neutral
• Price Target: $4.00 ▼(-10.11% Downside)

Karyopharm Therapeutics is facing severe financial challenges, with declining revenues, high leverage, and negative equity being the most significant factors. The technical analysis shows a bearish trend, and the valuation is poor due to ongoing losses. While the earnings call and corporate events highlight some positive developments, the financial constraints and strategic uncertainties weigh heavily on the overall score.

Positive Factors

Pipeline Development

New data from the Phase II XPORT-MF-035 study showed signs of spleen volume reduction and symptom improvement in pretreated myelofibrosis patients, indicating promising clinical progress.

Regulatory Approvals

Reimbursement approvals were received in the UK, Italy, France, China, and South Korea, highlighting positive market expansion.

Negative Factors

Capital and Financing

Current cash runway and recent failure to raise capital raise significant concern, affecting financial stability.

Clinical Trials

Potential risks include negative clinical data, slower-than-expected clinical development timelines, and setbacks in later-stage clinical studies, which could impact the company's growth prospects.

Financial Performance

KPTI reported net product revenue of $21.1M for Xpovio, which was below consensus estimates and down approximately 28% from the previous quarter, raising concerns about revenue generation.

Karyopharm Therapeutics Business Overview & Revenue Model

Company Description

Karyopharm Therapeutics Inc. (KPTI) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative therapies for the treatment of cancer and other serious diseases. The company focuses on leveraging its proprietary SINE compound technology platform to develop oral drugs that inhibit the nuclear export of proteins, thereby targeting key pathways involved in various malignancies. Karyopharm's core product candidates include Xpovio (selinexor), an FDA-approved treatment for multiple myeloma and certain types of lymphoma, along with a robust pipeline of investigational therapies aimed at diverse oncology indications.

How the Company Makes Money

Karyopharm Therapeutics generates revenue primarily through the sale of its approved drug Xpovio, which is marketed for the treatment of multiple myeloma and certain lymphomas. The company also earns revenue from collaborations and partnerships with other pharmaceutical and biotechnology companies, which may include upfront payments, milestone payments, and royalties on future sales. Additionally, Karyopharm may receive funding from government grants or research initiatives focused on cancer therapies. The company's ability to successfully navigate clinical trials and gain further regulatory approvals for its pipeline products will be pivotal in expanding its revenue streams.

Karyopharm Therapeutics Financial Statement Overview

Summary

Karyopharm Therapeutics faces significant financial challenges, including declining revenues, persistent losses, high leverage, and negative equity. Cash flow analysis shows insufficient operational cash generation, leading to reliance on external financing.

Income Statement

Karyopharm Therapeutics has experienced declining revenue over recent years, with a negative revenue growth rate of -0.55% from 2023 to 2024. The company also faces significant profitability challenges, as indicated by negative net profit margins and EBIT margins. Despite a relatively high gross profit margin of 95.87% in 2024, the persistent net losses highlight ongoing operational inefficiencies.

Balance Sheet

The balance sheet shows a concerning financial position with negative stockholders' equity, indicating liabilities exceed assets. The debt-to-equity ratio cannot be calculated due to negative equity, but the high total debt relative to assets suggests significant leverage. The equity ratio is negative, further emphasizing the financial instability and potential solvency risks.

Cash Flow

Karyopharm Therapeutics has negative free cash flow, which deteriorated by 37.66% from 2023 to 2024. The operating cash flow to net income ratio is negative, reflecting cash flow challenges. Although there was a positive financing cash flow, it is insufficient to offset the negative operating cash flow, indicating reliance on external financing.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	137.27M	145.24M	146.03M	157.07M	209.82M	108.08M
Gross Profit	132.29M	139.23M	141.09M	151.86M	206.42M	105.38M
EBITDA	-76.92M	-38.60M	-118.42M	-139.31M	-96.98M	-167.85M
Net Income	-123.57M	-76.42M	-143.10M	-165.29M	-124.09M	-196.27M
Balance Sheet
Total Assets	104.88M	164.42M	240.44M	358.17M	305.31M	313.05M
Cash, Cash Equivalents and Short-Term Investments	38.73M	108.71M	191.44M	277.97M	228.62M	249.24M
Total Debt	94.80M	194.52M	177.02M	179.07M	180.58M	131.13M
Total Liabilities	343.81M	350.44M	376.64M	374.83M	384.98M	262.50M
Stockholders Equity	-238.93M	-186.02M	-136.21M	-16.66M	-79.67M	50.55M
Cash Flow
Free Cash Flow	-102.89M	-127.63M	-92.72M	-149.67M	-112.83M	-160.38M
Operating Cash Flow	-102.94M	-127.49M	-92.72M	-149.55M	-107.12M	-160.23M
Investing Cash Flow	55.84M	95.47M	7.94M	-104.26M	141.84M	-53.69M
Financing Cash Flow	1.04M	41.65M	1.12M	193.74M	73.65M	172.08M

Karyopharm Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 4.45
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KPTI, the sentiment is Positive. The current price of 4.45 is above the 20-day moving average (MA) of 4.09, above the 50-day MA of 4.30, and below the 200-day MA of 7.52, indicating a neutral trend. The MACD of -0.09 indicates Negative momentum. The RSI at 55.21 is Neutral, neither overbought nor oversold. The STOCH value of 51.32 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for KPTI.

Karyopharm Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	60 Neutral	HK$18.14B	5.30	-4.00%	3.33%	10.16%	-17.39%
CNTB	49 Neutral	$125.65M	―	-58.89%	―	―	―
XFOR	44 Neutral	$29.43M	0.66	-207.22%	―	5721.31%	-671.01%
HOWL	42 Neutral	$53.85M	―	-82.81%	―	-92.95%	-50.02%
KPTI	41 Neutral	$34.86M	―	41.08%	―	-5.77%	-22.78%
PEPG	40 Underperform	$37.39M	―	-85.69%	―	―	10.04%

Karyopharm Therapeutics Corporate Events

Karyopharm Therapeutics Explores Financing and Strategic Options

Karyopharm Therapeutics has been in discussions with potential investors to explore financing options to extend its cash runway, but no transaction has been finalized. The company is evaluating strategic alternatives, including potential mergers or sales, to maximize shareholder value. Additionally, Karyopharm is reducing its workforce by 20% to manage operating expenses, while continuing to focus on its commercial and clinical efforts in multiple myeloma and myelofibrosis. The company reported a net product revenue of $21.1 million in the first quarter of 2025, with a total revenue of $30 million, despite being impacted by increased returns of expired products.

The most recent analyst rating on (KPTI) stock is a Buy with a $45.00 price target. To see the full list of analyst forecasts on Karyopharm Therapeutics stock, see the KPTI Stock Forecast page.

Karyopharm Therapeutics Stockholders Approve Equity Plan Amendment

At the 2025 Annual Meeting of Stockholders held on May 28, Karyopharm Therapeutics Inc. announced that its stockholders approved an amendment to the 2022 Equity Incentive Plan, increasing the number of shares available by 450,000. Additionally, Garen G. Bohlin and Zhen Su were elected as Class III directors for a three-year term. The stockholders also approved the compensation of the company’s named executive officers and recommended annual advisory votes on this compensation. Furthermore, Ernst & Young LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2025.

The most recent analyst rating on (KPTI) stock is a Buy with a $45.00 price target. To see the full list of analyst forecasts on Karyopharm Therapeutics stock, see the KPTI Stock Forecast page.